Veracyte (VCYT) Q1 2026 earnings review
Core Testing Engine Masks Biopharma Cliff as Profitability Surges
Veracyte delivered a stellar Q1, entirely driven by its core diagnostics portfolio. Total revenue grew 21% YoY to $139.1M, powered by a 26% surge in Testing revenue ($135.1M). The underlying volume metrics are highly stable: Decipher volume grew 24% and Afirma volume grew 12%. The most striking development, however, is the margin trajectory. Management previously framed 2026 as an 'investment year' with expected Adjusted EBITDA margins around 25% to fund new product launches. Instead, Q1 printed a massive 30.8% margin ($42.8M), forcing an immediate guidance raise for the full year. The core testing growth is successfully absorbing the complete collapse of the biopharma segment following the French subsidiary restructuring.
🐂 Bull Case
Decipher revenue surged 30% to $86.5M. The test continues to gain market share across the prostate cancer risk spectrum, effectively acting as the company's primary growth engine.
Non-GAAP gross margins expanded to 76% (up from 72% a year ago). The transition to the V2 transcriptome platform is paying off, demonstrating operating leverage that easily outpaces OpEx growth.
🐻 Bear Case
Biopharma revenue collapsed 92% to a mere $0.3M due to the liquidation of Veracyte SAS. Total revenue growth is entirely dependent on clinical testing volumes holding up.
The company relies heavily on the upcoming Prosigna LDT and TrueMRD launches to sustain long-term growth. Both enter highly competitive, well-penetrated markets.
⚖️ Verdict: 🟢
Bullish. The company is generating substantial cash ($35.2M in Q1) and upgrading its margin profile while maintaining >20% top-line growth. The biopharma drag is real but has been successfully insulated by the core testing portfolio.
Key Themes
Decipher Continues to Dominate
Decipher remains Veracyte's crown jewel. Volume grew 24% to 28,000 tests, outpacing total company volume growth (17%). Revenue growth was even stronger at 30% YoY ($86.5M), implying a healthy ASP environment. The completion of enrollment for GUIDANCE and G-MAJOR Phase III trials further deepens the clinical moat around the product.
Afirma V2 Platform Efficiencies Emerge
Afirma delivered stable, accelerating growth, with volumes up 12% (~17,200 tests) and revenue up 21% ($46.4M). Beyond the top line, the real driver is the ongoing transition to the V2 transcriptome platform. This shift has mechanically lowered 'no result' rates and reduced unit costs, serving as the primary catalyst for the 400 bps YoY expansion in Non-GAAP gross margin to 76%.
Biopharma Revenue Collapse Contradicts Total Growth Narrative
While management touted a 21% increase in total revenue, diving into the segments reveals a stark contradiction. Biopharma and other revenue completely collapsed, falling 92% YoY from $3.6M to $0.3M. This is an expected consequence of the Veracyte SAS liquidation proceedings, but it structurally removes a diversified revenue stream, putting 100% of the pressure on clinical testing to carry future quarters.
Under-Investing in the Innovation Pipeline?
In prior quarters, management explicitly stated 2026 Adjusted EBITDA margins would step down to ~25% to heavily fund the commercialization of Prosigna LDT and TrueMRD. Yet, Q1 delivered a 30.8% margin, and total non-GAAP operating expenses grew only 7% YoY ($64.6M) against 21% revenue growth. While investors love a profit beat, it raises a critical question: is Veracyte under-investing in its crucial upcoming product launches to protect near-term margins?
Execution Risk in Crowded Markets
The next leg of the company's growth relies on TrueMRD (muscle-invasive bladder cancer) and Prosigna LDT (breast cancer). Both markets are incredibly crowded. To succeed, Veracyte must flawlessly replicate its 'Decipher playbook' of evidence-driven commercialization against entrenched competitors with vast resources.
Macro Headwinds Offset by Operational Leverage
While the company acknowledges broader macro risks like inflation and volatile interest rates in its disclosures, actual operations show total immunity. The strategic shift to contract manufacturing and the new sequencing platforms have insulated cost of testing revenue, completely neutralizing inflationary pressures that are heavily impacting other diagnostic operators.
Other KPIs
A massive acceleration compared to $5.4 million generated in 25Q1. This underscores the incredibly high cash-conversion profile of the core testing business now that the cash-burning French SAS operations have been deconsolidated. The company ended the quarter with $439.1 million in cash, equivalents, and short-term investments, providing significant M&A firepower.
Reversing the historical pattern of GAAP unprofitability or single-digit margins, Net Income improved 307% YoY and represented an impressive 20.6% of revenue. This proves that the adjusted metrics are not merely accounting illusions but reflect true operational leverage.
Guidance
Accelerating. The company raised the range from the previous $570M - $582M. The new midpoint ($587M) implies an acceleration to 13.5% YoY growth, effectively absorbing the loss of the biopharma segment.
Accelerating. Raised from previous commentary, implying 16% to 18% YoY growth excluding contributions from new tests. This confirms that management sees no slowdown in the core Decipher and Afirma franchises through the remainder of the year.
Reversing previous caution. Coming into the year, management guided down to ~25% to account for heavy R&D and commercial investments for Prosigna and TrueMRD. Following Q1's 30.8% print, they have raised the floor to >26%.
Key Questions
Investment Cadence
Given the massive 30.8% Adjusted EBITDA margin in Q1 against full-year guidance of >26%, should we expect a sudden, massive ramp in commercial OpEx in Q2/Q3 for the TrueMRD and Prosigna launches, or are these product launches proving cheaper to commercialize than initially modeled?
Decipher Growth Longevity
Decipher continues to print 24%+ volume growth. What is the current estimated market penetration within your NCCN risk categories, and how much of this growth is coming from the newer metastatic launch versus core localized disease?
Biopharma Baseline
With Biopharma revenue essentially at zero ($0.3M) this quarter, is this the absolute floor, or are there lingering tail-revenue streams that will continue to roll off through the year?